Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tandem Diabetes Care filings document the company’s insulin delivery business, Nasdaq-listed common stock, operating results, governance matters, and capital structure. Recent 8-K reports furnish quarterly and annual financial results, guidance-related disclosures, and product or regulatory events tied to its diabetes technology portfolio.
The filing record also includes proxy materials for annual meeting voting, director elections, executive compensation, equity awards, and board committee matters. Material-event filings describe the company’s completed 0.00% convertible senior notes offering, related indenture terms, and FDA clearance for the SteadiSet wearable infusion set.
Tandem Diabetes Care reported higher sales and a sharply smaller loss for the quarter ended March 31, 2026. Sales rose to $247.2 million from $234.4 million, driven by pump and supply growth in both the United States and international markets. U.S. sales reached $160.8 million, while international sales were $86.4 million.
Gross profit increased to $136.8 million and gross margin improved to 55% from 51%, helped by better pricing, product mix, foreign exchange and lower material costs. Operating expenses dropped significantly to $154.2 million from $239.3 million, mainly because the prior year included $75.2 million of acquired in‑process research and development and lease impairment and restructuring charges that did not repeat.
Net loss narrowed to $20.4 million from $130.6 million, or $0.30 per share versus $1.97. Cash and cash equivalents rose to $179.3 million and short‑term investments to $390.9 million, supported by a new $300.0 million 0.00% Convertible Senior Notes due 2032, which increased total long‑term convertible debt to $601.8 million.
Tandem Diabetes Care reported improving first quarter 2026 results with reaffirmed full-year guidance. Sales reached $247.2 million, up 5% from $234.4 million, with $160.8 million from the United States and $86.4 million from international markets. The company shipped more than 29,000 insulin pumps worldwide and achieved a 55% gross margin, up from 51%.
GAAP operating loss narrowed sharply to $17.4 million from $120.9 million, and GAAP net loss improved to $20.4 million from $130.6 million. Adjusted EBITDA turned positive at $2.7 million versus negative $79.9 million, and free cash flow was $4.8 million compared to negative $21.2 million. Cash, cash equivalents and short-term investments increased to $570.3 million from $292.7 million, alongside a rise in convertible senior notes to $601.8 million from $310.0 million after closing a 0.00% convertible debt offering.
The company reaffirmed 2026 guidance, including expected sales of about $1.065 billion to $1.085 billion, gross margin of 56%–57% of sales, and adjusted EBITDA margin of 5%–6% of sales, supported by initiatives such as a pay-as-you-go reimbursement model and expansion of its Tandem Mobi ecosystem.
Voya Financial, Inc. reports beneficial ownership of Tandem Diabetes Care common stock. Voya states it beneficially owns 4,343,683 shares, representing 6.3% of the class, with 2,325,854 shares of sole voting power and sole dispositive power over all 4,343,683 shares. The report is filed by the ultimate parent on behalf of wholly owned subsidiaries and is signed by Voya's SVP, Chief Compliance and Deputy General Counsel.
Tandem Diabetes Care Inc Schedule 13G: Vanguard Capital Management reports beneficial ownership of 3,553,772 shares of Common Stock, representing 5.18% of the class. The filing lists 514,853 shares with sole voting power and 3,553,772 shares with sole dispositive power. The filing is signed by Vanguard's Head of Global Fund Administration.
Tandem Diabetes Care Inc reports that Vanguard Portfolio Management beneficially owned 4,052,274 shares of Common Stock, representing 5.91% of the class as reported on this Schedule 13G. The filing states Vanguard Portfolio Management exercises sole dispositive power over 4,052,274 shares and sole voting power over 58,941 shares, and that these holdings include securities held for Vanguard funds and managed accounts. The disclosure is signed by Ashley Grim as Head of Global Fund Administration.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos exercised restricted stock units and had shares withheld for taxes. On April 15, 2026, he converted 3,636 restricted stock units into an equal number of common shares at a $0.00 exercise price under a long-term incentive plan.
To cover tax withholding on the RSU vesting, 1,926 common shares were withheld by Tandem Diabetes Care Inc. at $20.66 per share, with no shares sold on the market. Following these transactions, he directly holds 25,772 shares of common stock and 18,181 restricted stock units.
Tandem Diabetes Care, Inc. is asking stockholders to approve a broad slate of governance, compensation and equity plan items at its 2026 virtual annual meeting on May 20, 2026. Investors will vote on electing nine directors for one-year terms and on a non-binding advisory approval of 2025 executive pay.
The company seeks approval to amend its 2023 Long-Term Incentive Plan to increase shares authorized for issuance by 3,260,000, supporting ongoing equity awards to employees, directors and other service providers. Stockholders are also asked to approve charter amendments aligning director removal rights with Delaware law and adding officer exculpation within newly expanded legal limits.
Other proposals include ratifying Ernst & Young LLP as independent auditor for 2026. The proxy highlights 2025 business results, including approximately $1.015 billion in worldwide sales and more than 126,000 annual pump shipments, and describes a pay-for-performance program where named executives earned 87% of target cash bonuses.
Tandem Diabetes Care is holding its 2026 Annual Meeting virtually on May 20, 2026 to vote on seven proposals, including election of nine directors, say-on-pay, an increase of 3,260,000 shares to the 2023 Long-Term Incentive Plan, certificate of incorporation amendments, and ratification of Ernst & Young LLP as auditor.
The Record Date shows 68,504,233 shares outstanding as of March 23, 2026. The company reports 2025 business highlights including $1.015 billion in worldwide sales, over 126,000 pump shipments, and several product and regulatory milestones.
The Vanguard Group filed Amendment No. 8 to a Schedule 13G/A for Tandem Diabetes Care, reporting 0 shares beneficially owned and 0% of the class as of the filing. The filing explains an internal realignment under SEC Release No. 34-39538 that caused certain subsidiaries or business divisions to report separately. The filing lists The Vanguard Group's address as 100 Vanguard Blvd., Malvern, PA and Tandem's principal executive office as 11075 Roselle Street, San Diego, CA. The form is signed by Ashley Grim, Head of Global Fund Administration on 03/27/2026.